This is a truly remarkable achievement that demonstrates the validity and application
of HUB organoids in high throughput screening and oncology drug discovery
San Diego, California, April 28, 2022 – Crown Bioscience , a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer , on a bispecific antibody whic h prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer.
The study was the result of work by an international consortium, SuppresSTEM which included Crown
Bioscience (previously OcellO B.V.) and HUB. Cro
wn Bioscience and HUB led the design of the
experiments which were executed using the high content screening platform from Crown Bioscience
using HUB Organoids. These studies enabled the discrimination of antibodies that were active against a
broad range
of mutational profiles and tumor subtypes, with hit validation and mechanism of action
studies that enabled selection of optimally performing antibodies. Follow up
in vivo
studies in matched
patient
-
derived xenograft (PDX) models were also performed by Cro
wn Bioscience.
The work, spanning about five years, involved Crown Bioscience screening a library of hundreds of
bispecific antibodies and rescreening of ‘hits’ in a panel of patient
-
derived colorectal cancer organoids
and matching normal organoids, tha
t were developed by HUB and characterized by HUB and other
consortium members. Organoids are stem cell
-
derived mini
-
organs developed from any patient
resection or biopsy tissue that can be grown in the laboratory, which can be applied like conventional
cel
l lines in early drug discovery.
“This is the first study that has used organoids exclusively for cell
-
based compound screening and
characterization, leading to a compound entering clinical trials. This is a truly remarkable achievement
that demonstrat
es the validity and application of HUB Organoids in high throughput screening and
oncology drug discovery”, said Leo Price PhD, Senior Vice President
In Vitro
Oncology at Crown
Bioscience.
“This groundbreaking work demonstrates the power and potential
of HUB Organoid Technology”,
commented Rob Vries PhD, CEO at HUB. “Using organoids, we were able to accelerate the timeline from
initial discovery to clinical trials to about five years.”
Nature Cancer
is a journal which covers the latest, most signific
ant cancer
-
related advances across the
life, physical, applied and social sciences, focusing on new approaches for the development and delivery
of diagnostics and therapeutics, as well as clinical studies regarding cancer diagnosis, treatment and
preventio
n.
Read the full paper here:
https://go.nature.com/3LhuAAy
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global cont
ract research organization (CRO) providing
preclinical and translational platforms to advance oncology, immuno
-
oncology, and immune
-
mediated
inflammatory diseases. The company is the only preclinical CRO to hold a commercial license to provide
tumor organo
id services utilizing HUB technology and has the world’s largest commercially available PDX
collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right
treatment at the right time. Founded in 2006, Crown Biosci
ence has nine facilities in the US, Europe and
Asia. Find out more:
https://www.crownbio.com
.
About HUB
HUB Organoids (HUB) is the global leader in the field of adult stem cell
-
derived organoid. The technology
invented by HUB’s scientists in the lab of world
-
renowned Prof. Hans Clevers represents a paradigm shift
for drug discovery and development, preclinic
al patient stratification, predictive diagnostics, personalized
medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its
proprietary technology and provides drug screening services and access to its living org
anoid biobanks.
About SupresStem
The SuppresSTEM consortium was funded by EU FP7 and involved collaborative work by companies
including OcellO B.V./Crown Bioscience, HUB Organoids, and Merus N.V., and international research
institutions including the Hub
recht Institute, IRB Barcelona and the Sanger Institute. The Vall d'Hebron
Institute of Oncology (VHIO), the Catalan Institute of Oncology and the company Xenopad also
collaborated in data for this publication. The consortium set out to develop novel antib
ody
-
based
therapeutics targeting cancer stem cells for the treatment of colorectal cancer as well as patient
-
derived
organoid
-
based screening tools to aid drug discovery.
Media Enquiries
Crown Bioscience
Louise
Stenson
